Copenhagen-based hearing aid manufacturer Oticon, part of the Demant Group (CPH: DEMANT) on Wednesday introduced Oticon Zeal, a new in-the-ear hearing aid designed to eliminate the traditional trade-off between discreet design and full functionality, marking the creation of a new hearing aid category, NXT In-the-Ear.
Oticon Zeal integrates the company's BrainHearing technology to deliver clear, natural sound in all environments via the use of second-generation AI sound processing. The device offers same-day fitting, all-day battery life, and seamless connectivity, targeting users who value both aesthetics and advanced performance.
The new model is powered by encapsulation technology, similar to that used in pacemakers, enabling compact construction with durability and high moisture resistance. Its triple-function antenna is designed to ensure strong wireless connectivity while maintaining a deep, secure in-ear fit.
Oticon Zeal supports Google's Fast Pair feature for Android users and incorporates Auracast technology for enhanced audio streaming in public venues. The device also features seamless, stable connectivity with Apple products and can be controlled through the Oticon Companion app.
The rechargeable lithium-ion battery provides up to 20 hours of operation, with quick charging options offering four hours of use from just 15 minutes of charge.
Oticon positions Zeal as a complement to its existing Oticon Intent line, expanding its portfolio to better address diverse hearing needs across global markets.
Neola Medical secures US patent for disposable lung monitoring probes
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Organon to sell JADA System to Laborie for up to USD465m
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Oticon launches Oticon Zeal, a discreet, fully featured in-the-ear hearing aid
Halozyme Therapeutics announces Q3 2025 release date
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia